佛慈制药(002644) - 2021 Q3 - 季度财报

Revenue and Profit - The company's revenue for the third quarter reached ¥277,343,937.75, representing a 59.56% increase year-over-year[3] - The net profit attributable to shareholders decreased by 64.58% to ¥22,211,549.24 for the third quarter[3] - The net profit excluding non-recurring gains and losses increased by 335.43% to ¥19,413,002.07 for the third quarter[3] - The company's net profit attributable to shareholders was RMB 641,652,803.79, compared to RMB 631,858,257.27 in the previous year, reflecting a slight increase[16] - The net profit for Q3 2021 was CNY 70,813,560.39, a decrease of 32.5% compared to CNY 105,030,464.38 in Q3 2020[17] - The total comprehensive income for the period was CNY 70,813,560.39, compared to CNY 105,030,464.38 in the previous year[18] - The total profit for the period was CNY 83,534,126.04, compared to CNY 123,899,928.90 in Q3 2020[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,512,217,384.44, a 5.24% increase from the previous year[3] - The total assets of the company as of September 30, 2021, were RMB 2,473,868,747.61, up from RMB 2,387,181,792.19 at the end of 2020, marking a growth of 3.6%[16] - Total liabilities increased to RMB 873,912,647.53 from RMB 800,082,432.94, reflecting a rise of 9.2%[15] Cash Flow - The cash flow from operating activities for the year-to-date was ¥77,172,989.83, an increase of 80.21%[3] - The net cash flow from operating activities was CNY 77,172,989.83, a significant improvement from a negative cash flow of CNY -15,268,871.85 in the same period last year[20] Receivables and Inventory - Accounts receivable increased by 115.00% to ¥390,775,356.48, primarily due to sales growth[6] - Accounts receivable increased significantly to RMB 390,775,356.48 from RMB 181,752,950.19, representing a growth of 115.5%[13] - Inventory levels rose to RMB 285,329,233.99, compared to RMB 258,325,810.00, indicating an increase of 10.4%[14] Expenses - The company’s sales expenses increased by 51.46% to ¥94,147,116.20, reflecting higher marketing costs[7] - Total operating costs amounted to RMB 609,281,078.12, up 27.9% from RMB 475,927,683.89 in the previous year[16] Government Support and Future Plans - The company received government subsidies amounting to ¥4,784,415.56 during the third quarter[5] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[11] Earnings Per Share - The company reported a basic earnings per share of ¥0.0435, up 129.33% compared to the same period last year[3] - Basic and diluted earnings per share were both CNY 0.1386, down from CNY 0.2060 in Q3 2020[18]